Proteomics International Laboratories Ltd

Equities

PIQ

AU000000PIQ0

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:53 2024-05-31 am EDT 5-day change 1st Jan Change
0.97 AUD -2.02% Intraday chart for Proteomics International Laboratories Ltd -4.90% +8.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Proteomics International Laboratories Supports Root Rot Study with Biomarker Platform MT
Proteomics International Signs Agreement with University of Oxford for Endometriosis Study MT
Proteomics Says PromarkerD's US Launch Delayed MT
Proteomics International Laboratories Secures ISO 13485 Certification Renewal MT
Proteomics International Laboratories Narrows Fiscal H1 Loss MT
Proteomics International Laboratories Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Proteomics International's Blood Test for Uterine Disease Undergoes Biomarker Validation MT
Proteomics International's Blood Test for Throat Cancer Undergoes Biomarker Validation MT
Proteomics International Laboratories Raises AU$6.5 Million for Test Commercialization, Further Development; Shares Down 10% MT
Proteomics Signs Deal to Sell PromarkerD in Chile; Shares Jump 5% MT
Proteomics International Laboratories Receives More than AU$1.8 Million R&D Tax Rebate MT
Proteomics International Laboratories Requests Extension of Securities Trading Suspension MT
Proteomics International Subsidiary Secures New Patent in Japan; Shares Fall 4% MT
Proteomics International Laboratories Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Proteomics International Laboratories Signs Deal to Commercialize Diagnostic Test in the US; Shares Rally 11% MT
Proteomics International Laboratories Renews ISO 13485 Certification, ISO 17025 Accreditation MT
Proteomics International Laboratories Verifies Effectivity of Endometriosis Diagnostic Test MT
Proteomics International Laboratories to Resubmit Medicare Application for Diagnostic Test in Australia MT
Proteomics International Laboratories Limited Announces to Resubmit Application for PromarkerD Listing on Australian Medicare Benefits Schedule CI
Proteomics International Laboratories Limited Provides Update on Exclusive Licence Agreement with Sonic Healthcare USA, Inc CI
Proteomics International Laboratories Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Proteomics International Laboratories Extends Predictive Test Distribution Agreement in Britain MT
Proteomics International Laboratories Ltd Extends its Distribution Agreement with Apacor Limited to Bring its PromarkerD Predictive Test for Diabetic Kidney Disease to Patients in England, Scotland and Wales CI
Proteomics International Laboratories Limited Announces Letter of Intent with Sonic Healthcare USA Extended CI
Proteomics International Laboratories Raises AU$1.8 Million from Options Exercise MT
Chart Proteomics International Laboratories Ltd
More charts
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.97 AUD
Average target price
1.38 AUD
Spread / Average Target
+42.27%
Consensus

Annual profits - Rate of surprise